OncoCyte Corporation (OCX)
NASDAQ: OCX · Real-Time Price · USD
3.220
+0.270 (9.15%)
Apr 24, 2025, 4:00 PM EDT - Market closed
OncoCyte Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for OncoCyte stock have an average target of 4.42, with a low estimate of 4.00 and a high estimate of 5.00. The average target predicts an increase of 37.27% from the current stock price of 3.22.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for OncoCyte stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
---|---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 2 | 2 |
Buy | 1 | 1 | 1 | 1 | 1 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 3 | 3 | 3 | 3 | 4 | 3 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Needham | Needham | Strong Buy Reiterates $4.25 | Strong Buy | Reiterates | $4.25 | +31.99% | Apr 8, 2025 |
Lake Street | Lake Street | Strong Buy Initiates $5 | Strong Buy | Initiates | $5 | +55.28% | Mar 28, 2025 |
Stephens & Co. | Stephens & Co. | Hold Reiterates $4 | Hold | Reiterates | $4 | +24.22% | Mar 26, 2025 |
Stephens & Co. | Stephens & Co. | Hold Reiterates $4 | Hold | Reiterates | $4 | +24.22% | Mar 25, 2025 |
Needham | Needham | Strong Buy Reiterates $4.25 | Strong Buy | Reiterates | $4.25 | +31.99% | Mar 25, 2025 |
Financial Forecast
Revenue This Year
1.03M
from 1.88M
Decreased by -45.03%
Revenue Next Year
3.87M
from 1.03M
Increased by 274.47%
EPS This Year
-1.08
from -4.66
EPS Next Year
-0.89
from -1.08
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 |
---|---|---|---|
High | 1.7M | 6.4M | 13.9M |
Avg | 1.0M | 3.9M | 13.3M |
Low | 392,000 | 1.9M | 12.9M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 |
---|---|---|---|
High | -10.7% | 519.4% | 258.0% |
Avg | -45.0% | 274.5% | 244.3% |
Low | -79.2% | 80.1% | 234.1% |
EPS Forecast
EPS | 2025 | 2026 | 2027 |
---|---|---|---|
High | -0.87 | -0.79 | -0.83 |
Avg | -1.08 | -0.89 | -0.80 |
Low | -1.50 | -0.99 | -0.77 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 |
---|---|---|---|
High | - | - | - |
Avg | - | - | - |
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.